Dr. Greenbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1660 S Columbian Way
Seattle, WA 98108Phone+1 206-277-4757
Summary
- I am a board-certified medical oncologist who works in drug development.
Education & Training
University of Washington School of MedicineFellowship, Oncology/Bmt, 2015 - 2019
University of California (San Diego) Medical CenterResidency, Internal Medicine, 2013 - 2015
Washington University in St. Louis School of MedicineClass of 2012, MD/PhD
Washington University in St. LouisBS, Computer Science, Magnum Cum Laude, 2001 - 2005
Certifications & Licensure
CA State Medical License 2014 - Present
WA State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Mar 23
- Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Start of enrollment: 2018 Jul 09
Publications & Presentations
PubMed
- Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor-Adoptive T-cell Therapy.George Mo, Sang Y Lee, David G Coffey, Valentin Voillet, Ilan R Kirsch
Blood Cancer Discovery. 2024-07-01 - 5 citationsDiffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8T-cells despite immune checkpoint signaling.Adam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, A McGarry Houghton
Blood Research. 2022-06-30 - Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.Adam Greenbaum, Damian J. Green, Leona Holmberg, Ted Gooley, Brian G. Till
Blood Research. 2018-09-01
Abstracts/Posters
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin LymphomasAdam Greenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic TrialsAdam Greenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Links to the ACC.22 Late-Breaking Clinical TrialsApril 13th, 2022
Grant Support
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)National Institutes of Health2009–2012
- Research Training Award for FellowsAmerican Society of HematologyPresent
Research History
- Postdoctoral fellowMechanisms of Immune Failure in Non-Hodgkin Lymphoma2016 - Present
- Ph.D. studentHematopoietic stem cells (HSCs) reside in the bone marrow supported by the surrounding stromal compartment. Using a novel conditional knockout of CXCL12 to delete the gene from four stromal compartments, I demonstrated that HSCs are supported by mesenchymal stem cells.2007 - 2011
Professional Memberships
- Member
- Member
- Society for Immunotherapy of CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
